JKT · SRAJ.JK
PT Sejahteraraya Anugrahjaya Tbk
IDR 10,850-IDR 125 (-1.14%)
PT Sejahteraraya Anugrahjaya Tbk’s quoted price sits in the lower half of its reported 52-week range, 43.49% below the high.
Loading market information…
JKT · PEHA.JK · IDR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · IDR. Historical prices are not a forecast.
PT Phapros, Tbk’s quoted price sits in the lower half of its reported 52-week range, 44.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
PT Phapros, Tbk’s forward annual dividend is IDR 13 per share, paid annual. The forward yield is 5.26% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PT Phapros, Tbk’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PT Phapros, Tbk is a prominent Indonesian company operating within the pharmaceutical and healthcare sectors. Its operations are broadly categorized into four key divisions: Over-the-Counter (OTC) products, Ethical drugs, Generic drug manufacturing, and Toll Manufacturing services. The company's OTC offerings feature well-known brands such as Antimo Anak, Livron B Plek, Noza, Hemorogard, and Bioron. In addition to supplying generic medications to government institutions and hospitals, PT Phapros also serves as a contract manufacturer for other pharmaceutical companies and provides various medical devices. Established in 1954 with its headquarters located in Jakarta, Indonesia, the company further extends its market reach by exporting products internationally. PT Phapros, Tbk functions as a subsidiary under the umbrella of PT Kimia Farma (Persero) Tbk.
Latest available per-share figures in IDR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
IDR 10,850-IDR 125 (-1.14%)
PT Sejahteraraya Anugrahjaya Tbk’s quoted price sits in the lower half of its reported 52-week range, 43.49% below the high.
IDR 730+IDR 15 (+2.1%)
PT Kalbe Farma Tbk.’s quoted price sits in the lower half of its reported 52-week range, 45.52% below the high.
IDR 123-IDR 2 (-1.6%)
UBC Medical Indonesia Tbk.’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
IDR 123+IDR 1 (+0.82%)
PT Royal Prima Tbk’s quoted price sits in the upper half of its reported 52-week range, 8.21% below the high.
IDR 278-IDR 2 (-0.71%)
PT Diagnos Laboratorium Utama Tbk’s quoted price sits in the upper half of its reported 52-week range, 27.23% below the high.
IDR 198IDR 0 (0.0%)
PT Millennium Pharmacon International Tbk’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
IDR 24-IDR 2 (-7.69%)
PT Nanotech Indonesia Global Tbk’s quoted price sits in the lower half of its reported 52-week range, 64.18% below the high.
IDR 58-IDR 3 (-4.92%)
PT Hetzer Medical Indonesia Tbk’s quoted price sits in the lower half of its reported 52-week range, 63.06% below the high.
